Who are Emalex's investors?

Emalex's investors include Paragon Biosciences LLC, Valor Equity Partners, Bain Capital Life Sciences, Fidelity Investments.

Emalex

30,270 employees on LinkedIn · 4 known investors

Find your way into Emalex

Paths you didn't know you had: your email and LinkedIn already hold routes to the Emalex team. We find them
2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a lead investigational asset, ecopipam, a selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company, created by Paragon Biosciences, advanced ecopipam through Phase 3 development and was acquired by Teva Pharmaceutical Industries in June 2026.

Biotech Digital Health

Investors · 4

Paragon Biosciences LLC✓ confirmed by EmalexChicago

How we know: the company's own site · funding news · paragonbiosci.com · Not right? Tell us

Valor Equity Partnerslisted by Valor Equity PartnersChicago

How we know: Valor Equity Partners's portfolio page · funding news · paragonbiosci.com · the VCSheet dataset · Not right? Tell us

Bain Capital Life SciencesreportedBoston

How we know: biospace.com · Not right? Tell us

Fidelity InvestmentsreportedBoston

How we know: funding news · paragonbiosci.com · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountSeries DNov 2022
Bain Capital Life Sciences (lead), Fidelity Management & Research Company, Paragon Biosciences, Valor Equity Partners
Source ↗
Undisclosed amountSeries CMar 2021
Paragon Biosciences (lead), Fidelity Management & Research Company LLC, Valor Equity Partners
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Emalex do?: Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a lead investigational asset, ecopipam, a selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company, created by Paragon Biosciences, advanced ecopipam through Phase 3 development and was acquired by Teva Pharmaceutical Industries in June 2026.
Who are Emalex's investors?: Emalex's investors include Paragon Biosciences LLC, Valor Equity Partners, Bain Capital Life Sciences, Fidelity Investments.